significant differences in the pharmacokinetics of midazolam (a CYP3A4 substrate) or on the formation of its active metabolite (1-hydroxymidazolam) were observed when a single 7.5- mg dose of midazolam was administered prior to and after a 14-day regimen of VYNDAQEL 20-mg once daily. ...
Newborns (0 to 3 months) at Risk for Cardiac Failure: Consider a lower initial dose; increase dose every 4 to 6 weeks as needed based on clinical and laboratory response Pediatric Patients at Risk for Hyperactivity: Initial dose should be one-fourth the recommended full replacement dose; increa...